Innovent Announces Phase 3 CREDIT-5 Study Met Primary Endpoint, SINTBILO® (Tafolecimab Injection) as First-line Monotherapy Treatment for Hyperlipidemia Demonstrated Potent Lipid-lowering Efficacy
SINTBILO® (tafolecimab injection) monotherapy achieved significant reduction of LDL-C level, with > 60% mean LDL-C reduction after 12 weeks of treatment with 150 mg Q2W/450 mg Q4W SINTBILO® (tafolecimab injection) monotherapy significantly decreased non-HDL-C, vLDL-C, ApoB, and Lp(a)...
Covered in this story
Call it yourself
No calls on $HDL yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Super Hi International Holding →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.